





To the Editor: The report of a 
human cutaneous leishmaniasis case 
acquired in Clairvaux-les-lacs (1) 
led us to carry out an investigation 
with the veterinary clinics in Jura 
Department, France. Clairvaux-les-
lacs is a lakeside resort located in 
Jura, one of the areas in France with 
the coldest average temperatures, and 
is clearly located outside the usual 
leishmaniasis-endemic area. At least 
31 cases of canine leishmaniasis were 
diagnosed by veterinary clinics in Jura 
during 2007–2011. Because these 
dogs were native of or traveled in the 
leishmaniasis-endemic area along the 
Mediterranean Sea, all veterinarians 
considered the infections as acquired 
outside Jura.
Although phlebotomine sand fl ies 
have not been reported in Jura to date, 
Phlebotomus perniciosus sand fl ies, 
proven vectors of leishmaniasis, have 
been found in 2 areas neighboring 
Jura: Côte-d’Or and Saône-et-Loire 
(2,3). We have also recently caught 
P. mascittii sand fl ies, a species with 
an unknown vectorial competence, 
in the Swiss region of Jura, Alsace, 
Champagne-Ardennes, and Belgium. 
Therefore, the presence of sand fl ies 
in Jura, particularly in wet and milder 
microclimatic areas (as Clairvaux-les-
lacs), is likely, and canine infections 
could have been acquired locally.
A recent model predicted that 
new at-risk areas are mostly located in 
western France along the Atlantic coast 
(4). In accordance with this model, 
we report new foci of autochthonous 
canine leishmaniasis in Deux Sèvres, 
Loire-Atlantique, and Loiret. Canine 
leishmaniasis cases contracted in the 
Rhine Valley in Germany (5) and 
the canine cases in Jura argue for a 
northeastern spread of the disease-
endemic area along the Rhone-
Rhine axis and mild microclimatic 
niches. Entomologic and serologic 
surveys will be carried out in summer 
2012 in Jura to look for evidence of 
possible indigenous transmission 
of leishmaniasis. These data should 
supplement the current model of 
northern spread of leishmaniasis-
endemic areas.
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Etymologia: Prion
To the Editor: The January 2012 
Etymologia section might confuse 
readers because it incorrectly reports 
that “prion” describes a noninfectious 
agent (1). In fact, prion—pronounced 
pree’-on—is a term coined in 1982 
by Nobel laureate Stanley Prusiner 
to describe the novel infectious agent 
responsible for scrapie, a transmissble 
neurodegenerative disorder of sheep 
and goats. He proposed his new 
term to underscore that the agents 
are “small proteinaceous infectious 
particles” resistant to procedures that 
attack nucleic acids (2). In his seminal 
article, he summarized experimental 
data indicating that the molecular 
properties of this infectious agent 
differed from those of other infectious 
agents, including viruses, viroids, 
and plasmids; he proposed the word 
prion to replace other terms then in 
circulation, such as “unconventional 
virus” or “unusual slow virus–like 
agent.”
Although Dr. Prusiner acknow-
ledged that he could not exclude the 
possibility of a small nucleic acid 
contained within the interior of the 
prion particle, now 3 decades later, 
no nucleic acid in the agent has yet 
been identifi ed. Increasingly accepted 
in the scientifi c community, prions 
are now considered to be a class of 
misfolded proteinaceous, infectious 
agents responsible for several types 
of human and animal transmissible 
spongiform encephalopathies. Their 
evolving defi ning characteristics 
classically include at least partial 
protease resistance, insolubility, and 
transmissibility. The term, prions, 
usually refers to the complete 
transmissible proteinaceous particles 
in nature or to their classically present, 
transmissible, protease-resistant 
oligomer cores, composed of protein 
fragments with molecular masses of 
≈27–30 kDa.
Adding confusion to the 
terminology, it has become customary 
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for prion researchers to refer to the 
normal nonpathogenic conformation 
of prions as “cellular prion proteins” 
(3). When these normal cellular prion 
precursors convert to pathogenic 
prion proteins, the transmissible 
conformations are characterized by 
β-pleated sheets rather than the normal 
α-helix structure, and they do not elicit 
an immune response (4).
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 To the Editor: Kaba et al. (1) 
reported a seroprevalence of 11.6% 
for hepatitis E virus (HEV) among 
homeless persons in the city of 
Marseille, located in southern France, 
and a multivariate analysis suggested 
that injection drug use (IDU) was 
an independent risk factor for HEV 
transmission. We disagree with this 
reported fi nding. 
We conducted a retrospective 
subanalysis of results from a multicenter 
therapeutic trial assessing HEV 
seroprevalence among HIV/hepatitis 
C co-infected patients in France (2). 
Serum samples from 84 IDU patients, 
enrolled during 2000–2002 were stored 
at −80°C. The mean ± SD age of the 
patients was 39 ± 4 years; 53 (63%) 
were men, 19 (23%) were born outside 
France, and 38 (45%) were living 
in southern France. HEV antibodies 
were tested with the same assay as 
that used by Kaba et al. (1), and HEV 
RNA was detected by using a real-time 
reverse transcription PCR amplifying 
open reading frame 3 (3). None of the 
patients had detectable IgM against 
HEV or HEV RNA. Test results for 3 
(3.6%) patients were positive for HEV 
IgG. Two of them lived in southern 
France, resulting in a 5.3% (2/38) HEV 
prevalence for IDU patients living in 
this region, where HEV IgG prevalence 
for healthy blood donors has reportedly 
ranged from 9% to 16.6% (4).
The difference between our study, 
which demonstrated low HEV IgG 
prevalence in IDU patients, even in 
southern France, and the results from 
Kaba et al. (1) must be interpreted with 
caution because there were several 
epidemiologic differences between 
the 2 populations. Moreover, there 
is a risk for false-negative serologic 
results for HIV patients because of 
impaired immunity, and the predictive 
value of serologic testing is probably 
low because of the artifi cially low 
HEV prevalence reported for this 
population. Despite these limitations, 
our study suggests that the high 
prevalence of HEV infection among 
homeless persons in southern France 
was not infl uenced by IDU, but 
refl ected the general epidemiology of 
HEV in this region.
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